About Aidea-Jiangsu Aidea Pharmaceutical Co., Ltd. (aidea.com.cn)

The company was renamed "Jiangsu Aidea Pharmaceutical Group Co., Ltd."
The marketing application for Atribond® new drug was approved by the Zambia Food and Drug Administration (ZFDA)
Phase III clinical trial of the novel integrase inhibitor ACC017 was officially launched
ADB116 for injection, an improved new drug in the stroke field, was approved for clinical trials
Dr. Heliang Fu released the Phase II clinical results of Asuptegravir at the 10th Medical Innovation and Investment Conference
ADC118 Tablets, a Class 1 new drug in the anti-HIV field, was approved for clinical trials

Acquired control of Nanda Pharmaceutical to achieve "human-derived protein raw material-preparation integration"
Won the Second Prize of Jiangsu Provincial Science and Technology Award in 2023
Marketing application for the new indication of Ainuomiti Tablets was approved
Selected as a National Specialized, Sophisticated, Unique and New "Little Giant" Enterprise
Marketing application for Ainuovirine API was approved, and mass production officially started
Two of the company's anti-AIDS innovative drugs were included in the Chinese Guidelines for the Diagnosis and Treatment of AIDS (2024 Edition)
Selected into the "2023 China Small Molecule Drug Enterprise Innovation Power TOP30 Ranking"
The wholly-owned subsidiary "Chengdu Aidea" grandly commenced operations
Won the title of "2023 Yangzhou Private Enterprise Innovation Top 20"
Re-certified as a "High-Tech Enterprise"
Won the title of "2023 Advanced Enterprise in Work Safety"

The company was selected into the "2022 China Small Molecule Drug Enterprise Innovation Power TOP30 Ranking"
The company was awarded "Enterprise with the Most Investment Value of the Year" at the 3rd Jiangsu Capital Market Summit
Co-built the China AIDS Prevention and Control Innovative Drug Research Demonstration Base
Aitribond® (Ainuomiti/ACC008 Tablets) was included in the National Medical Insurance Catalog, and Ainuovirine/ACC007 Tablets successfully renewed its contract

Aitribond® (Ainuomiti/ACC008 Tablets) has been approved for marketing
Signed a Strategic Cooperation Agreement with the Chinese Association of STD & AIDS Prevention and Control (CASAPC)

Ainuovirine Tablets was included in the national reimbursement drug list. .
Ainuovirine Tablets was approved for marketing.
Raw material of Ulinastatin won the title of "Specialized, Fined, Peculiar and Innovative Product of Jiangsu Province”.
The company received Provincial Special Funds for the Development of Strategic Emerging Industries of Jiangsu in 2021
The company won the title " Model Unit of Yangzhou 2019-2020".

Aidea Pharma was successfully listed on the SSE STAR Market (stock abbreviation: Aidea Pharma, stock code: 688488)
Ainuovirine obtained the Notification of Drug Registration Application Acceptance

Ulinastatin for injection obtained clinical trial approval
Aidea Pharma completed the shareholding reorganization and was renamed as "Jiangsu Aidea Pharmaceutical Co., Ltd.".
ACC008 was included into the national 13th Five-Year Plan Science and Technology Major Projects as"Major New Drug Development".
ACC010 obtained clinical trial approval.
Nanjing Accelas Pharmaceutical Technology Co., Ltd. was recognized as one of the Nanjing Antiviral Drug R&D Engineering and Technology Research Centers.

Ainuovirine compound tablets (ACC008) obtained the approval letter for drug clinical trial.
Aidea Pharma obtained the pharmaceutical GMP certificate.
Ainuovirine obtained the provincial special funds for enterprise innovation and achievement transformation in 2018.

Ainuovirine, a national first class anti-AIDS new drug, was entitled as one of the national 13th Five-Year Plan Science and Technology Major Projects of "Major New Drug Development".
Ainuovirine, a national first class anti-AIDS new drug, obtained the approval letter for drug clinical trial.
Aidea Pharma set up a Jiangsu postgraduate workstation.

Aidea Pharma obtained the strategic investments from Jiangsu Hi-Tech Investment Company, Huatai Securities and STARR.
Aidea Pharma has been recognized as one of the Jiangsu Enterprise Technology Centers.
A wholly owned acquisition of Yangzhou Xingdou Pharmaceutical, and renamed as Yangzhou Aidea Pharmaceutical Co., Ltd.

Crude human urinary kallidinogenase was recognized as high-tech products by Jiangsu Province in 2014.
Aidea Pharma has been recognized as the Human Urine Protein Engineering Technology Research Center of Jiangsu Province
Aidea Pharma established the enterprise academician workstation.

The "R&D and Industrialization Project on Fresh Flow Adsorption Technology of Active Protein and Processes for Large-scale Preparation of Ulinastatin and Albumin” obtained the provincial special fund for enterprise innovation and achievement transformation in 2013.
"Development of the fresh flow adsorption method for industrial-scale production of crude Ulinastatin" won the first prize of the science and technology award.
Establishment of the subsidiary corporation Nanjing Accelas Pharmaceutical Technology Co., Ltd.
Raw material of urokinase by fresh flow adsorption was recognized as high-tech products by Jiangsu Province in 2013

Aidea Pharma was included in the key project list of the Yangzhou Engineering and Technology Research Center in 2012.
Aidea Pharma was recognized as one of the Yangzhou Enterprise Technology Centers in 2012.
Crude Ulinastatin containing lower content of vasoactivity substances was recognized as high-tech products by Jiangsu Province in 2012

The crude urinary albumin was recognized as high-tech products by Jiangsu Province in 2011.
Aidea Pharma was awarded as "High-tech Enterprise".

Crude Ulinastatin was recognized as high-tech products by Jiangsu Province in 2010.

Establishment of Yangzhou Aidea Biotechnology Co., Ltd. (predecessor of Aidea Pharma)